Xenetic Biosciences is trading 5.79% lower at $2.11, with biotech-sector weakness offering only partial context. - The XBI ETF was down 2.01% pre-market. No new company announcement was identified for October 2; the latest listed press release is the September 16 share-exchange agreement with Santersus. - Broader stocks were higher after weaker-than-expected September payrolls. Volume was 12.83K versus an average daily volume of 101.61K.